The global single-use bioreactors market, valued at US$4.1 billion in 2023, is forecasted to grow at a robust CAGR of 15.4%, reaching US$4.4 billion in 2024 and an impressive US$9.1 billion by 2029. Growth in this market can be attributed to factors such as increasing adoption among CDMOs, CMOs, and SMEs, advantages over conventional bioreactors, reduced capital investment, lower water and energy consumption, and the expanding biologics and biosimilars markets. On the other hand, issues related to extractables and leachables, regulatory hurdles and compliance challenges, and the impact of PFAS restrictions on product development are expected to hinder market growth.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=49113750
Browse in-depth TOC on "Single-Use Bioreactors Market"
408 - Tables
48 - Figures
345 - Pages
The monoclonal antibodies segment accounted for the largest share of the type of molecule segment in the single-use bioreactors market
Based on the type of molecule, the global single-use bioreactors market is segmented into monoclonal antibodies (mAbs), vaccines, gene-modified cells, stem cells, and other molecules. The monoclonal antibodies segment accounted for the largest share of the global single-use bioreactors market in 2022 owing to increasing demand for single-use bioreactors in the manufacturing of mAbs, and factors such as low investment costs and a reduction in time-intensive changeover procedures.
The mammalian cells segment accounted for the fastest growing share of the type of cell segment in the single-use bioreactors market
Based on the type of cell, the global single-use bioreactors market is segmented into mammalian cells, bacterial cells, yeast cells, and other cells. In 2022, the mammalian cells segment accounted for the largest share of the market owing to increasing adoption of mammalian cells due to their post-translational modification capacity and human protein-like molecular structure assembly are expected to propel market growth.
The Asia Pacific region is the fastest-growing region of the single-use bioreactors market
Based on the region, the single-use bioreactors market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to register the highest CAGR during the forecast period. Factors such as the growing biopharmaceutical industry, rising investments by pharmaceutical & biotechnology companies, and the growing number of CROs & CMOs in several Asia Pacific countries are supporting the growth of the market in the region.
Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=49113750
Key Market Players:
Key players in the single-use bioreactors Market are Sartorius AG (Germany), Thermo Fisher Scientific (US), Danaher Corporation (US), and Merck Millipore (Germany).
Sartorius AG provides an extensive range of single-use bioreactor products for end users such as biopharmaceutical & pharmaceutical companies, CMOs, and CROs. The company’s strong focus on a broad range of customer-centric and technology-enabled solutions, significant investments in R&D, and a comprehensive product line comprising high-quality products are contributing to its growing share in the single-use bioreactors market. With a strong geographic presence and continuous expansions in developed and developing regions, the company is expected to grow at a high rate in the single-use bioreactors market during the forecast period.
Danaher Corporation provides cell culture, filtration, separation, and purification technologies for the medical, biopharmaceutical, and food & beverage industries through its subsidiary, Cytiva (a part of the Life Sciences business). The company is one of the top players in the single-use bioreactors market with its strong portfolio of single-use bioreactors solutions. Its bioprocessing single-use technologies facilitate the development and commercialization of chemically synthesized and biologically derived drugs, plasma, and vaccines.
Thermo Fisher Scientific, Inc. offers a broad spectrum of single-use bioreactor products. This wide array allows it to serve diverse market needs effectively. As a leading player with a high market share, it has significant influence over market trends and customer preferences, leveraging its established reputation to maintain leadership. Continuous investment in R&D ensures the company remains at the forefront of technological advancements, addressing emerging challenges and opportunities in bioprocessing.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=49113750
Comments
0 comment